Archive · 28 Aug 2026
Temple Acquires Longevous Ahead of Experimental Wearable Launch
Deepinder Goyal’s company Temple has acquired a London-based practice called Longevous.
Longevous studies ways to help people stay healthier for longer.
Its founders, Robert Mohr and Avi Roy, will now work full-time at Temple.
Mohr will become the company’s chief medical officer.
Roy will become its head of science.
Temple is developing a small device worn near the side of the head.
The company says it can measure signals related to blood flow and oxygen levels in the brain.
Mohr and Roy tested the device for about two months and reviewed Temple’s early scientific work.
However, the device’s main scientific claims have not yet been confirmed by published peer-reviewed research.
Deepinder Goyal’s health-tech startup Temple acquired London-based longevity medicine practice Longevous for undisclosed terms.
Longevous founders Robert Mohr and Avi Roy, along with their team, will join Temple full-time.
Mohr will become Temple’s chief medical officer and oversee clinical rigor for its experiments and health claims.
Roy will become Temple’s head of science and lead its scientific efforts.
Temple’s wearable is designed to monitor cerebral blood flow and oxygenation; its Entropy metric remains unsupported by published peer-reviewed evidence.
- Who
- Temple, founded by Deepinder Goyal; Longevous founders Robert Mohr and Avi Roy; and the Longevous team.
- What
- Temple acquired Longevous, with its founders taking senior clinical and scientific roles at Temple.
- When
- Goyal announced the acquisition on Thursday; the articles do not provide an exact date. Pre-orders are expected shortly, with shipments planned before the end of 2026.
- Where
- Longevous is based in London, where Goyal first met Mohr and Roy.
- Why
- Temple said the acquisition will strengthen its clinical and scientific expertise ahead of the wearable’s launch and help evaluate its experiments and claims.
Temple’s Device Claims
Evidence Caveat
Scientific validation
Temple’s Device Claims
Temple says its wearable can collect real-time signals related to cerebral blood flow and oxygenation, and that its Entropy metric provides a real-time measure of metabolic cost.
Evidence Caveat
The articles state that the claims underpinning Entropy have not yet been established through published peer-reviewed evidence.
Role of the acquisition
Temple’s Device Claims
Temple says Mohr and Roy bring clinical expertise, publication experience and scientific scrutiny that will support validation before launch.
Evidence Caveat
The device remains experimental and is not yet available to consumers, with Temple’s main claims still awaiting published peer-reviewed confirmation.
- Acquirer
- Temple, a health-tech startup founded by Deepinder Goyal
- Acquired practice
- Longevous, a London-based longevity medicine practice
- Financial terms
- Not disclosed
- New chief medical officer
- Robert Mohr
- New head of science
- Avi Roy
- Wearable purpose
- Designed to monitor cerebral blood flow, oxygenation and heart-rate-related signals in real time
- Product status
- Not yet available to consumers; shipments are planned before the end of 2026
- Longevous operations
- Longevous will continue operating under Temple, with Mohr and Roy seeing existing clients
